Categories: CHF

Araris Biotech AG Supported with CHF 2.5M Swiss Accelerator Grant from Innosuisse to Develop Antibody-Drug Conjugate Candidates

Innosuisse supports 53 companies out of 752 applications with total CHF 112M Araris’ awarded grant will be used to support further development and advancement of Araris’ antibody-drug conjugate (ADC) …
Read Full Story at source (may require registration)

Latest posts by Business Editor (see all)
Business Editor

Leave a Comment
Share
Published by
Business Editor
2 years ago

Recent Posts

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zynex, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZYXI

NEW YORK, April 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights…

5 hours ago

Writer/painter-turned cultural heritage preserver behind Spring Festival’s UNESCO heritage status success

Global Times: Feng Jicai leads efforts to preserve China's cultural heritage through art, literature, and…

6 hours ago

Boston Hemp Launches New Line of Premium THCa Concentrates

Hanover, MA , April 20, 2025 (GLOBE NEWSWIRE) -- Boston Hemp Inc., a leader in…

7 hours ago

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Bakkt Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BKKT

NEW YORK, April 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights…

7 hours ago

Kyndryl Announcement: If You Have Suffered Losses in Kyndryl Holdings, Inc. (NYSE: KD), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, April 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor…

8 hours ago

Australian Dollar Speculative Net Positions Improve, But Remain in the Negative

The latest data release from the Commodity Futures Trading Commission (CFTC) reveals a marginal improvement…

14 hours ago

This website uses cookies.